I last wrote about OraSure Technologies (NASDAQ: OSUR ) in November of 2024. At the time, the company's shares were trading at roughly $4 a share. Since then, OSUR has dipped to below $3 per share (at the time of this writing). In this article, we will touchI am a value investor with a concentrated portfolio, focusing on rare and exceptional buying opportunities. As a keen reader of Value Investing literature, I am well versed in the teachings of 'super investors' such as Warren Buffett, Charlie Munger, Ben ...

BETHLEHEM, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2025 financial results and certain business developments for 5 p.m. ET on May 7, 2025. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 mi ...

BETHLEHEM, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (the "Company") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that its Board of Directors has authorized the repurchase of up to $40 million of its common stock over the next twenty-four months, which will be funded from cash on hand. The Company may repurchase the shares through various methods in compliance with applicable state and federal securities laws. Th ...

FORM 10-K __________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ | __________________________________________________________ Delaware | 36-4370966 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employ ...

Financial Data and Key Metrics Changes - Total revenue in Q4 was $37.4 million, with core revenue of $36.5 million, reflecting a 10% year-over-year increase [28][29] - GAAP gross margin for Q4 was 36.2%, while non-GAAP gross margin was 40.1%, slightly below expectations due to lower margins in the risk assessment business and higher scrap expenses [31][32] - The company ended Q4 with zero debt and total cash and cash equivalents of $268 million [33] Business Line Data and Key Metrics Changes - Diagnostics revenue grew 9% year-over-year, generating $18.8 million in Q4, driven by strong order trends in the international HIV business [29][13] - Sample management solutions revenue increased 14% year-over-year, totaling $14.8 million in Q4 [29][13] - COVID-19 products contributed $1 million in revenue, consistent with expectations, while the risk assessment testing business generated $2.1 million in Q4 [30] Market Data and Key Metrics Changes - The international diagnostics business generated $41 million in revenue for 2024, with approximately 80% associated with donor-funded programs [15][16] - The company noted elevated uncertainty in the market environment due to freezes on US funding for foreign aid, impacting HIV testing programs in developing countries [15][19] Company Strategy and Development Direction - The company is focused on three strategic pillars: strengthening the foundation, elevating core growth, and accelerating profitable growth [7] - The acquisition of Sherlock Biosciences aims to expand the innovation pipeline with a molecular diagnostic platform [8][24] - The company plans to invest in innovation and expand its product portfolio, particularly in rapid diagnostics and sample management solutions [23][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong positioning despite near-term uncertainties, emphasizing the importance of investments in science and innovation [21][41] - The company is closely monitoring the impact of external factors, including changes in funding for HIV testing programs and NIH research funding [15][19] - Management anticipates that the combination of operational efficiencies and increased volumes will drive gross margin improvements towards the target of 50% [36] Other Important Information - The company generated positive cash flow from operations for the core business in Q4, indicating progress in operating efficiency and cost-saving initiatives [11][12] - The company expects to spend between $20 million and $25 million on the Sherlock acquisition, primarily for clinical trial development [95] Q&A Session Summary Question: What are the key uncertainties in the global market? - Management identified PEPFAR and academic funding as the primary areas of uncertainty, with PEPFAR being closely monitored [44][46] Question: Any updates on the Safarose blood collection device? - The device is still in the regulatory process, with expectations for approval in 2025 [50][51] Question: Can you elaborate on the BARDA contract and its funding? - The $7.5 million from BARDA is expected to be back-end loaded, with potential access to an additional $11 million based on milestones [55][56] Question: What is the outlook for gross margins and scrap expenses? - Scrap expenses were attributed to expired materials and are considered a one-time issue, with expectations for gross margins to improve through operational efficiencies [59][60] Question: How does the company view the potential downside from international government-funded markets? - Management emphasized bipartisan support for life-saving programs and the importance of public health, framing the international business as primarily donor-funded [102][106]

OraSure Technologies (OSUR) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -200%. A quarter ago, it was expected that this diagnostic test maker would post a loss of $0.04 per share when it actually produced a loss of $0.01, delivering a surprise of 75%.Over the last four quarters, the c ...

Revenue Performance - Q4 2024 total net revenues decreased 51% to $37.4 million from $75.9 million in Q4 2023, primarily due to a decline in COVID-19 revenues[6] - Core business revenues increased 10% year-over-year to $36.5 million in Q4 2024, with diagnostics revenues up 9% to $18.8 million and sample management solutions revenues up 14% to $14.8 million[6] - COVID-19 revenues fell 98% year-over-year to $1.0 million in Q4 2024, following the completion of a major government contract[6] - Revenue for Q4 2024 was $37.445 million, a decrease from $75.881 million in Q4 2023, representing a decline of 50.7%[24] - For Q1 2025, the company anticipates revenues between $27.5 million and $31.5 million, with core revenues expected to be $27 million to $31 million[8] Profitability and Loss - The company reported a GAAP operating loss of $12.4 million in Q4 2024, compared to an operating income of $3.9 million in Q4 2023[6] - Non-GAAP Net Income for the year 2024 was a loss of $4.230 million, compared to a profit of $66.311 million in 2023, reflecting a significant decline[24] - GAAP Net Income for the year 2024 was a loss of $19.500 million, compared to a profit of $53.655 million in 2023[24] - Non-GAAP Operating Loss for Q4 2024 was $6.745 million, compared to an operating income of $11.151 million in Q4 2023[24] - GAAP Earnings Per Share for Q4 2024 was $(0.14), down from $0.27 in Q4 2023[24] - Non-GAAP Earnings Per Share for Q4 2024 was $(0.06), compared to $0.18 in Q4 2023[24] - The company reported a GAAP Operating Loss of $12.418 million for Q4 2024, compared to an operating income of $3.898 million in Q4 2023[24] Margins - GAAP gross margin for Q4 2024 was 36.2%, down from 46.3% in Q4 2023, while non-GAAP gross margin was 40.1%, down from 46.5%[6] - GAAP Gross Margin for Q4 2024 was 36.2%, down from 46.3% in Q4 2023, indicating a decrease of 10.1 percentage points[24] Cash Flow and Assets - Cash and cash equivalents stood at $267.8 million as of December 31, 2024, with cash flow from operations at $0.1 million for Q4 2024[6] - Total assets decreased from $482,845 million in December 31, 2023 to $480,859 million in December 31, 2024, a decline of approximately 0.4%[14] - Cash and cash equivalents decreased from $290,407 million in December 31, 2023 to $267,763 million in December 31, 2024, a decrease of about 7.8%[16] - Cash provided by operating activities dropped from $141,583 million in 2023 to $27,374 million in 2024, a decrease of approximately 80.7%[16] Expenditures and Compensation - Capital expenditures decreased from $10,303 million in 2023 to $3,797 million in 2024, a reduction of about 63.2%[15] - Stock-based compensation increased from $10,729 million in 2023 to $11,920 million in 2024, an increase of approximately 11.1%[15] - Stock compensation expenses for the year 2024 amounted to $11.919 million, up from $10.729 million in 2023[24] - The company recognized a reduction in workforce severance costs of $1.366 million for the year 2024, compared to $369,000 in 2023[24] Inventory and Receivables - Accounts receivable decreased from $40,171 million in December 31, 2023 to $23,816 million in December 31, 2024, a decline of about 40.6%[14] - Inventories decreased from $47,614 million in December 31, 2023 to $34,197 million in December 31, 2024, a decrease of approximately 28.2%[14] Strategic Initiatives - The company acquired Sherlock Biosciences in December 2024 to enhance its innovation pipeline with a new molecular diagnostics platform[6] - The company plans to wind down its Risk Assessment testing business while continuing to support existing customers during the first half of 2025[12] - The company is focused on expanding its product portfolio and market presence, particularly in rapid diagnostic tests and sample management solutions[18] Impairments - The company reported a loss on impairments of $4,392 million in 2024, compared to $10,829 million in 2023, indicating a reduction in impairment losses[16]

Core Insights - OraSure Technologies reported a 51% decrease in total net revenues for Q4 2024, amounting to $37.4 million, down from $75.9 million in Q4 2023, primarily due to a significant decline in COVID-19 revenues [3][9] - Core revenues, excluding COVID-19 and Molecular Services, increased by 10% year-over-year to $36.5 million, with diagnostics revenues rising by 9% to $18.8 million and sample management solutions revenues increasing by 14% to $14.8 million [3][9] - The company made strategic advancements in 2024, including the acquisition of Sherlock Biosciences, which is expected to enhance its diagnostic capabilities [2][9] Financial Performance - For the three months ended December 31, 2024, the gross profit was $13.6 million, resulting in a gross margin of 36.2%, compared to 46.3% in the same period of 2023 [4][9] - The operating loss for Q4 2024 was $12.4 million, compared to an operating income of $3.9 million in Q4 2023, indicating a significant operational challenge [4][9] - The net loss for Q4 2024 was $10.8 million, contrasting with a net income of $20.1 million in Q4 2023, reflecting the impact of reduced revenues [4][9] Business Developments - The company received FDA approval for a labeling change to the OraQuick® HIV Self-Test, expanding its use to adolescents aged 14 and older [9] - OraSure is developing a rapid antigen test for Marburg Virus Disease, supported by a contract valued at approximately $7.5 million, with potential total value up to $11 million [9] - The company is winding down its Risk Assessment testing business while continuing to support existing customers [9] Financial Guidance - For Q1 2025, the company anticipates revenues between $27.5 million and $31.5 million, with core revenues expected to be between $27 million and $31 million [7]

Core Viewpoint - OraSure Technologies, Inc. is set to hold its earnings conference call for the fourth quarter of 2024 on February 25, 2025, at 5 p.m. ET, to discuss financial results and business developments [1]. Company Overview - OraSure Technologies, Inc. focuses on transforming health through actionable insights and enhancing access to healthcare via innovative testing and sample management solutions [3]. - The company, along with its subsidiaries DNA Genotek Inc. and Sherlock Biosciences, Inc., is a leader in developing, manufacturing, and distributing rapid diagnostic tests and sample collection devices [3]. - OraSure's products are sold globally to various sectors, including clinical laboratories, hospitals, physician's offices, public health organizations, research institutions, government agencies, and pharmaceutical companies [3].

Investors might want to bet on OraSure Technologies (OSUR) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by ...